Fox Chase Cancer Center

Fox Chase Cancer Center (FCCC) is a distinguished medical research institution specializing in comprehensive cancer research, clinical trials, and innovative medical investigations. As a registered federal grant recipient, FCCC demonstrates expertise in advanced medical research, particularly in oncological studies, clinical trials, and translational research methodologies. The center appears to be a robust academic medical research organization that collaborates with multiple prestigious medical institutions to advance scientific understanding of complex medical conditions and potential treatment interventions.

The federal grant sub-awards reveal FCCC's significant involvement in sophisticated medical research projects, with recent awards focused on specialized clinical investigations. In September 2024, FCCC received a sub-award from The General Hospital Corporation for a multisite randomized clinical trial examining a novel digital application (SHIFT) designed to improve outcomes for hematopoietic stem cell transplant survivors, specifically targeting sexual health outcomes, quality of life, and psychological distress. Additionally, FCCC has participated in sub-awards with Cedars-Sinai Medical Center and other institutions, engaging in advanced RNA and single-cell RNA sequencing research, including experimental studies on signaling mechanisms in mouse models. The center's research capabilities extend to complex data analysis, experimental design, participant recruitment, protocol development, and collaborative scientific investigations across multiple medical domains, with key personnel including researchers like Dr. Jennifer Reese and Dr. Henry Fung providing critical scientific and clinical expertise.